

CARCINOMA OF THE EYELID

| |
|------------------------------|
| Hospital Name/Address |
|------------------------------|

| |
|---------------------------------|
| Patient Name/Information |
|---------------------------------|

Type of Specimen _____

Histopathologic Type _____

Tumor Size _____

Laterality: ☐ Bilateral ☐ Left ☐ Right

DEFINITIONS

| Clinical | Pathologic | Primary Tumor (T) |
|--------------------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> | <input type="checkbox"/> | TX Primary tumor cannot be assessed |
| <input type="checkbox"/> | <input type="checkbox"/> | T0 No evidence of primary tumor |
| <input type="checkbox"/> | <input type="checkbox"/> | Tis Carcinoma <i>in situ</i> |
| <input type="checkbox"/> | <input type="checkbox"/> | T1 Tumor of any size, not invading the tarsal plate or, at the eyelid margin, 5 mm or less in greatest dimension |
| <input type="checkbox"/> | <input type="checkbox"/> | T2 Tumor invades tarsal plate or, at the eyelid margin, more than 5 mm but not more than 10 mm in greatest dimension |
| <input type="checkbox"/> | <input type="checkbox"/> | T3 Tumor involves full eyelid thickness or, at the eyelid margin, more than 10 mm in greatest dimension |
| <input type="checkbox"/> | <input type="checkbox"/> | T4 Tumor invades adjacent structures, which include bulbar conjunctiva, sclera and globe, soft tissues of the orbit, perineural space, bone and periosteum of the orbit, nasal cavity and paranasal sinuses, and central nervous system |

| Clinical | Pathologic | Regional Lymph Nodes (N) |
|--------------------------|--------------------------|--------------------------------------------|
| <input type="checkbox"/> | <input type="checkbox"/> | NX Regional lymph nodes cannot be assessed |
| <input type="checkbox"/> | <input type="checkbox"/> | N0 No regional lymph node metastasis |
| <input type="checkbox"/> | <input type="checkbox"/> | N1 Regional lymph node metastasis |

| Clinical | Pathologic | Distant Metastasis (M) |
|-------------------------------------------------------------------------------------------------------|--------------------------|------------------------------------------|
| <input type="checkbox"/> | <input type="checkbox"/> | MX Distant metastasis cannot be assessed |
| <input type="checkbox"/> | <input type="checkbox"/> | M0 No distant metastasis |
| <input type="checkbox"/> | <input type="checkbox"/> | M1 Distant metastasis |
| Biopsy of metastatic site performed <input type="checkbox"/> Y <input type="checkbox"/> N | | |
| Source of pathologic metastatic specimen _____ | | |

Stage Grouping

No stage grouping is presently recommended

Histologic Grade (G)

- ☐ GX Grade cannot be assessed
- ☐ G1 Well differentiated
- ☐ G2 Moderately differentiated
- ☐ G3 Poorly differentiated
- ☐ G4 Undifferentiated or differentiation is not applicable

Residual Tumor (R)

- ☐ RX Presence of residual tumor cannot be assessed
- ☐ R0 No residual tumor
- ☐ R1 Microscopic residual tumor
- ☐ R2 Macroscopic residual tumor

(continued on reverse side)

Additional Descriptors

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

- ☐ **m suffix** indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.
- ☐ **y prefix** indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy.
- ☐ **r prefix** indicates a recurrent tumor when staged after a disease-free interval, and is identified by the “r” prefix: rTNM.
- ☐ **a prefix** designates the stage determined at autopsy: aTNM.

Prognostic Indicators (if applicable)

Notes

Additional Descriptors

Lymphatic Vessel Invasion (L)

LX Lymphatic vessel invasion cannot be assessed

L0 No lymphatic vessel invasion

L1 Lymphatic vessel invasion

Venous Invasion (V)

VX Venous invasion cannot be assessed


V0 No venous invasion

V1 Microscopic venous invasion

V2 Macroscopic venous invasion

ILLUSTRATION

Indicate on diagram primary tumor and regional nodes involved.



Physician's Signature _____ Date _____